Clinical Report: Nordic Pharma Launches Lacrifill® Canalicular Gel in Europe
Overview
Nordic Pharma has launched Lacrifill®, a novel cross-linked hyaluronic acid gel for dry eye management, in Europe. This therapy temporarily occludes the canalicular system, enhancing tear film preservation and providing long-lasting effects for up to six months.
Background
Dry eye disease affects up to 30% of the European population and poses challenges, particularly for patients undergoing ocular surgeries like cataract or LASIK. Achieving a stable ocular surface is crucial for successful surgical outcomes, making effective management of dry eye essential. The introduction of Lacrifill® offers a new therapeutic option for optimizing ocular surface health pre- and post-operatively.
Data Highlights
No numerical data available in the source material.
Key Findings
- Lacrifill® is designed to temporarily block tear drainage by occluding the canalicular system.
- The gel enhances tear film preservation, maintaining natural lubrication on the ocular surface.
- It provides long-lasting effects for up to six months following an in-office procedure.
- Dry eye disease is prevalent in up to 30% of the European population, impacting surgical outcomes.
- Professor Jose Benitez del Castillo emphasizes the importance of stable ocular surfaces for successful surgeries.
Clinical Implications
Lacrifill® represents a significant advancement in the management of dry eye disease, particularly for patients preparing for ocular surgery. Its ability to enhance tear film stability may improve surgical outcomes and patient satisfaction.
Conclusion
The launch of Lacrifill® in Europe marks an important development in dry eye management, providing healthcare professionals with a new tool to optimize ocular surface health.
References
- Nordic Pharma, Ophthalmology Management, 2025 -- Nordic Pharma Announces European Launch of Lacrifill® Canalicular Gel
- Ophthalmology Management — QUICK HITS
- Ophthalmology Management — May 1
- Ophthalmology Management — Rx Perspective: Hyaluronic Acid Plays New Role in DED Treatment
- Ophthalmology Management — The Latest News in Ophthalmology
- QUICK HITS
- May 1 News Quick Notes
- Rx Perspective: Hyaluronic Acid Plays New Role in DED Treatment
- TFOS DEWS III: Management and Therapy
- How effective and safe are punctal plugs in treating dry eye disease? A systematic review and meta-analysis - ScienceDirect
- https://lacrifill.com/wp-content/uploads/2024/03/NORD_7000_Lacrifill_Instructions_for_Use-V5_FNL_VIEWONLY.pdf
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
